Prophylactic Effects of NFκB Essential Modulator–Binding Domain Peptides on Bone Infection: An Experimental Study in a Rabbit Model

References

• Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369–379. doi:10.1016/S0140-6736(04)16727-5
   PubMed Web of Science ®Google Scholar
• Pincus DJ, Armstrong MB, Thaller SR. Osteomyelitis of the craniofacial skeleton. Semin Plast Surg. 2009;23(2):73–79. doi:10.1055/s-0029-1214159
   PubMedGoogle Scholar
• Baur DA, Altay MA, Flores-Hidalgo A, Ort Y, Quereshy FA. Chronic osteomyelitis of the mandible: diagnosis and management–an institution’s experience over 7 years. J Oral Maxillofac Surg. 2015;73(4):655–665. doi:10.1016/j.joms.2014.10.017
   PubMed Web of Science ®Google Scholar
• Haeffs TH, Scott CA, Campbell TH, Chen Y, August M. Acute and chronic suppurative osteomyelitis of the jaws: a 10-year review and assessment of treatment outcome. J Oral Maxillofac Surg. 2018;76(12):2551–2558. doi:10.1016/j.joms.2018.05.040
   PubMed Web of Science ®Google Scholar
• Bury DC, Rogers TS, Dickman MM. Osteomyelitis: diagnosis and treatment. Am Fam Physician. 2021;104(4):395–402.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem. 2000;275(7):4858–4864. doi:10.1074/jbc.275.7.4858
   PubMed Web of Science ®Google Scholar
• Yamashita M, Otsuka F, Mukai T, et al. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol. 2008;196(3):601–613. doi:10.1677/JOE-07-0532
   PubMed Web of Science ®Google Scholar
• Sacco R, Shah S, Leeson R, et al. Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review. Br J Oral Maxillofac Surg. 2020;58(1):25–33. doi:10.1016/j.bjoms.2019.09.023
   PubMed Web of Science ®Google Scholar
• Taddio A, Zennaro F, Pastore S, Cimaz R. An update on the pathogenesis and treatment of chronic recurrent multifocal osteomyelitis in children. Paediatr Drugs. 2017;19(3):165–172. doi:10.1007/s40272-017-0226-4
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20(3):345–357. doi:10.1210/edrv.20.3.0367
   PubMed Web of Science ®Google Scholar
• Deutschmann A, Mache CJ, Bodo K, Zebedin D, Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics. 2005;116(5):1231–1233. doi:10.1542/peds.2004-2206
   PubMed Web of Science ®Google Scholar
• Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem. 2001;276(1):563–568. doi:10.1074/jbc.M008198200
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kim DW, Kwak YT, Prajapati S, Verma U, Gaynor RB. IKKgamma /NEMO facilitates the recruitment of the IkappaB proteins into the IkappaB kinase complex. J Biol Chem. 2001;276(39):36327–36336. doi:10.1074/jbc.M104090200
   PubMed Web of Science ®Google Scholar
• Claro T, Widaa A, McDonnell C, Foster TJ, O’Brien FJ, Kerrigan SW. Staphylococcus aureus protein A binding to osteoblast tumour necrosis factor receptor 1 results in activation of nuclear factor kappa B and release of interleukin-6 in bone infection. Microbiology. 2013;159(Pt 1):147–154. doi:10.1099/mic.0.063016-0
   PubMed Web of Science ®Google Scholar
• Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–558. doi:10.1038/nri.2017.52
   PubMed Web of Science ®Google Scholar
• Strickland I, Ghosh S. Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis. 2006;65 Suppl 3(Suppl3):iii75–iii82. doi:10.1136/ard.2006.058438
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang L, Mu X, et al. Development of novel NEMO-binding domain mimetics for inhibiting IKK/NF-κB activation. PLoS Biol. 2018;16(6):e2004663. doi:10.1371/journal.pbio.2004663
   PubMed Web of Science ®Google Scholar
• Luo Q, Li D, Bao B, et al. NEMO-binding domain peptides alleviate perihematomal inflammation injury after experimental intracerebral hemorrhage. Neuroscience. 2019;409:43–57. doi:10.1016/j.neuroscience.2019.04.041
   PubMed Web of Science ®Google Scholar
• Sun Y, Li X, Zhang L, et al. Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer. Mol Pharm. 2019;16(3):1140–1155. doi:10.1021/acs.molpharmaceut.8b01123
   PubMed Web of Science ®Google Scholar
• Tas SW, Vervoordeldonk MJ, Hajji N, May MJ, Ghosh S, Tak PP. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther. 2006;8(4):R86. doi:10.1186/ar1958
   PubMed Web of Science ®Google Scholar
• Clohisy JC, Yamanaka Y, Faccio R, Abu-Amer Y. Inhibition of IKK activation, through sequestering NEMO, blocks PMMA-induced osteoclastogenesis and calvarial inflammatory osteolysis. J Orthop Res. 2006;24(7):1358–1365. doi:10.1002/jor.20184
   PubMed Web of Science ®Google Scholar
• Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem. 2004;279(36):37219–37222. doi:10.1074/jbc.C400258200
   PubMed Web of Science ®Google Scholar
• Liu YD, Yang HX, Liao LF, et al. Systemic administration of strontium or NBD peptide ameliorates early stage cartilage degradation of mouse mandibular condyles. Osteoarthr Cartil. 2016;24(1):178–187. doi:10.1016/j.joca.2015.07.022
   PubMed Web of Science ®Google Scholar
• Reay DP, Yang M, Watchko JF, et al. Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis. 2011;43(3):598–608. doi:10.1016/j.nbd.2011.05.008
   PubMed Web of Science ®Google Scholar
• Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med. 2004;10(6):617–624. doi:10.1038/nm1054
   PubMed Web of Science ®Google Scholar
• Li W, Yu B, Li M, et al. NEMO-binding domain peptide promotes osteoblast differentiation impaired by tumor necrosis factor alpha. Biochem Biophys Res Commun. 2010;391(2):1228–1233. doi:10.1016/j.bbrc.2009.12.048
   PubMed Web of Science ®Google Scholar
• Nijhof MW, Stallmann HP, Vogely HC, et al. Prevention of infection with tobramycin-containing bone cement or systemic cefazolin in an animal model. J Biomed Mater Res. 2000;52(4):709–715. doi:10.1002/1097-4636(20001215)52:4<709::AID-JBM16>3.0.CO;2-W
   PubMed Web of Science ®Google Scholar
• Norden CW, Myerowitz RL, Keleti E. Experimental osteomyelitis due to Staphylococcus aureus or Pseudomonas aeruginosa: a radiographic-pathological correlative analysis. Br J Exp Pathol. 1980;61(4):451–460.
   PubMedGoogle Scholar
• Smeltzer MS, Thomas JR, Hickmon SG, et al. Characterization of a rabbit model of staphylococcal osteomyelitis. J Orthop Res. 1997;15(3):414–421. doi:10.1002/jor.1100150314
   PubMed Web of Science ®Google Scholar
• Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018;149(4):313–323. doi:10.1007/s00418-018-1640-6
   PubMed Web of Science ®Google Scholar
• An J, Yang H, Zhang Q, et al. Natural products for treatment of osteoporosis: the effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci. 2016;147:46–58. doi:10.1016/j.lfs.2016.01.024
   PubMed Web of Science ®Google Scholar
• Oviedo-Boyso J, Cortés-Vieyra R, Huante-Mendoza A, et al. The phosphoinositide-3-kinase-Akt signaling pathway is important for Staphylococcus aureus internalization by endothelial cells. Infect Immun. 2011;79(11):4569–4577. doi:10.1128/IAI.05303-11
   PubMed Web of Science ®Google Scholar
• Zhu F, Yue W, Wang Y. The nuclear factor kappa B (NF-κB) activation is required for phagocytosis of staphylococcus aureus by RAW 264.7 cells. Exp Cell Res. 2014;327(2):256–263. doi:10.1016/j.yexcr.2014.04.018
   PubMed Web of Science ®Google Scholar
• Lan Y, Xie H, Shi Y, et al. NEMO‑binding domain peptide ameliorates inflammatory bone destruction in a Staphylococcus aureus‑induced chronic osteomyelitis model. Mol Med Rep. 2019;19(4):3291–3297. doi:10.3892/mmr.2019.9975
   PubMed Web of Science ®Google Scholar
• Xu CP, Chen Y, Sun HT, et al. Efficacy of NEMO-binding domain peptide used to treat experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus: an in-vivo study. Antimicrob Resist Infect Control. 2019;8:182. doi:10.1186/s13756-019-0627-y
   PubMed Web of Science ®Google Scholar
• Prokuski L. Prophylactic antibiotics in orthopaedic surgery. J Am Acad Orthop Surg. 2008;16(5):283–293. doi:10.5435/00124635-200805000-00007
   PubMed Web of Science ®Google Scholar
• Gollwitzer H, Roessner M, Langer R, et al. Safety and effectiveness of extracorporeal shockwave therapy: results of a rabbit model of chronic osteomyelitis. Ultrasound Med Biol. 2009;35(4):595–602. doi:10.1016/j.ultrasmedbio.2008.10.004
   PubMed Web of Science ®Google Scholar
• May MJ, D’Acquisto F, Madge LA, Glöckner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science. 2000;289(5484):1550–1554. doi:10.1126/science.289.5484.1550
   PubMed Web of Science ®Google Scholar